Brought to you by 
Merckle acquires Technilab Pharma
14 Jul 2000
Executive Summary
Merckle has agreed to acquire Technilab Pharma (Montreal-based generics company) for $4.13 ($Cdn6.10) per share, a (pr)46% premium based on the market average, for a total of $54.7mm. Members of the Sabourin family, who owned about 65% of the outstanding shares, irrevocably tendered their shares in this transaction.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merckle acquires Technilab Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice